Kit for rapidly detecting single nucleotide polymorphism of human SLCO1B1 gene and application thereof

Through the combination of CRISPR/Cas12b system and maltodextrin protective agent, the cold chain dependence problem of SLCO1B1 gene detection is solved, and rapid and accurate detection is achieved at room temperature, suitable for applications in grassroots hospitals, and supports the promotion of precise medication and POCT technology. .

CN118910249APending Publication Date: 2024-11-08HANGZHOU YITAI HEALTH MANAGEMENT CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411218814.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing single nucleotide polymorphism detection method for SLCO1B1 gene is complex in operation and requires cold chain storage and transportation, which limits its application in grassroots hospitals and low-level medical areas, and has the risk of experimental error.

Method used

Using a vitrification premix kit based on CRISPR/Cas12b system, the fluorescence brightness under naked eye blue light is observed by naked eyes, and the rapid detection of the SLCO1B1 gene c.388A>G and c.521T>C sites are achieved, which eliminates cold chain dependence and uses Maltodextrin acts as a protective agent to maintain enzyme activity.

Benefits of technology

It realizes rapid and accurate SLCO1B1 genotyping detection at room temperature, reduces experimental errors, is suitable for on-site testing in grassroots communities, supports precise medication use, and promotes the application of nucleic acid POCT technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910249A_ABST
    Figure CN118910249A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly discloses a kit for rapidly detecting human SLCO1B1 gene single nucleotide polymorphism and application thereof.The kit comprises two vitrification premixing reagents, nuclease-free water and a colorimetric card, each vitrification premixing reagent is composed of 20 microliters of reaction premixing liquid and a protective agent, and c.388Agt is detected; in the vitrification premixing reagent of the G site, the sgRNA sequence is as shown in SEQ ID NO. 2; the c.521 Tgt is detected; in the vitrification premixing reagent of the C site, the sgRNA sequence is as shown in SEQ ID NO.7. According to the method, constant-temperature, rapid and accurate typing detection of the SLCO1B1 gene can be realized on site, the dependence on a cold chain is eliminated, the requirements of primary community screening are preliminarily met, technical support is provided for precise medication of patients with hyperlipidemia of different genotypes, and popularization and application of a field detection technology are facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a kit for rapidly detecting single nucleotide polymorphism of human SLCO1B1 gene and application thereof. Background Art

[0002] Hyperlipidemia is a disease caused by systemic fat metabolism disorder, which leads to an imbalance in the lipid structure. Statins are currently the most widely used lipid-lowering drugs in clinical practice. During clinical application, it was found that there are certain individual differences in the efficacy and safety of statins in different patients. Studies have shown that the polymorphism of related genes is closely related to the efficacy of statins. Single nucleotide polymorphism (SNP) is a DNA sequence polymorphism caused by the variation of a single nucleotide at the genomic level. For most SNPs, although located in the coding region, they will not affect the amino acid sequence and will not affect the performance of the individual; some SNPs located in the coding region may affect the function of the protein by affecting translation, thereby causing changes in the amino acid sequence. The polymorphism of related genes such as receptors and transporters involved in the metabolism of statins may have a certain impact on the safety and effectiveness of statins. Among them, organic anion transporting polypeptide (OATP1B1) is involved in the transport of multiple drugs. In the metabolism of statins, it is responsible for transferring drugs in the blood to the liver to directly exert their efficacy or metabolize them into active substances. It is encoded by the SLCO1B1 gene located on chromosome 12. The mutant SLCO1B1 gene causes the encoded OATP1B1 transporter to weaken, which is manifested as a decrease in the liver's ability to take up drugs, causing an increase in the blood concentration of statins and increasing the risk of rhabdomyolysis or myopathy. There are two main single nucleotide polymorphisms in the SLCO1B1 gene, namely c.388A>G and c.521T>C, which can form four haplotypes, including SLCO1B1*1b (388G-521T), SLCO1B1*15 (388G-521C), SLCO1B1*5 (388A-521C), and SLCO1B1*1a (388A-521T). Testing these genotypes can help better select the type and dose of statin suitable for the patient to optimize treatment effect and reduce the risk of adverse reactions.

[0003] With the development of molecular biology, many genotyping methods for single nucleotide polymorphisms have been developed. The existing detection methods for SLCO1B1 double-site nucleotide polymorphism mainly include sequencing, high melting point fluorescence quantitative PCR, digital PCR, etc. However, the operation process of these nucleic acid detection methods is cumbersome, and the requirements for the detection environment, equipment and operators are high, which limits their application in grassroots hospitals, especially in areas with relatively low medical and health levels. In order to promote the role of nucleic acid detection in precision medicine, nucleic acid point-of-care testing (POCT) came into being. POCT is a new method for rapid on-site detection extended from the field of in vitro diagnostics, which can achieve rapid and immediate diagnosis of nucleic acids at the bedside, public health emergency sites, grassroots medical institutions and other occasions. However, since the biologically active substances in nucleic acid detection kits must maintain activity at low temperatures, this has largely limited the development of POCT. Medical institutions need a large amount of refrigerated space to store these reagents, which is not available at many detection sites; if the operator preserves the reagents improperly or freezes and thaws repeatedly during storage, it will also cause certain experimental errors; in addition, nucleic acid detection reagents need to rely on special cold chain transportation, and the equipment is complex and costly. Therefore, how to solve these problems and achieve the optimized development of nucleic acid POCT is an important challenge facing the current in vitro diagnostic industry.

[0004] In order to make the nucleic acid detection of key metabolic gene polymorphisms of statins reach the grassroots level and get rid of cold chain transportation, the present invention provides a kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene and its application. Summary of the invention

[0005] The purpose of the present invention is to provide a kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene and its application in view of the defects of the prior art, so as to solve the problems raised by the above-mentioned background technology.

[0006] To achieve the above-mentioned object, the present invention provides the following technical scheme: a kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene, comprising two vitrified premixed reagents for detecting two SNP sites c.388A>G and c.521T>C, nuclease-free water and a colorimetric card, respectively, the two vitrified premixed reagents are composed of 20 μL reaction premixed solution and a protective agent, wherein, in the vitrified premixed reagent for detecting the c.388A>G site, the sgRNA sequence is shown as SEQ ID NO.2; in the vitrified premixed reagent for detecting the c.521T>C site, the sgRNA sequence is shown as SEQ ID NO.7.

[0007] As a preferred technical solution of the present invention, the reaction premix contains 600nM Cas12b protein, 250nM sgRNA, 10×Cas12b reaction buffer, 20U RNase inhibitor, and 500nM single-stranded DNA fluorescent probe.

[0008] As a preferred technical solution of the present invention, the sequence of the single-stranded DNA fluorescent probe is 5'-FAM-TTATT-BHQ1-3'.

[0009] As a preferred technical solution of the present invention, the protective agent in the vitrification premix reagent is maltodextrin with a concentration of 0.10 to 0.30 g / mL.

[0010] As a preferred technical solution of the present invention, the concentration of maltodextrin is 0.20 g / mL.

[0011] As a preferred technical solution of the present invention, the preparation process of the vitrified premixed reagent is as follows:

[0012] After the reaction premix is ​​fully mixed with the protective agent, it is placed in a vacuum drying oven for drying at a pumping pressure of 90 to 100 KPa, a drying temperature of 15 to 25° C., and a drying time of 4 to 6 hours.

[0013] As a preferred technical solution of the present invention, the pumping pressure is 97 KPa, the drying temperature is 22° C., and the drying time is 5.4 h.

[0014] A kit is used for detecting single nucleotide polymorphism of SLCO1B1 gene, and the specific detection operation steps are as follows:

[0015] Step 1: Take 1 portion of each of the two vitrified premixed reagents and place them in PCR tubes. Add 20 μL of nuclease-free water to each tube to dissolve the vitrified premixed reagents.

[0016] Step 2: Add 100 ng human genomic DNA sample to each tube;

[0017] Step 3: react at 48°C for 30 min;

[0018] Step 4: Illuminate with a blue light meter, observe the fluorescence brightness with the naked eye, and compare it with the colorimetric card; the brightest one is the mutant homozygote, the second brightest one is the heterozygote, and the one with no fluorescence is the wild-type homozygote.

[0019] Compared with the prior art, the beneficial effects of the present invention are as follows: the present invention establishes a constant temperature one-tube rapid detection method for detecting the polymorphisms of SLCO1B1 gene c.388A>G and c.521T>C based on CRISPR / Cas12b system technology, which can be observed only by the naked eye combined with naked eye blue light observation, and uses room temperature vitrification technology to solidify the CRISPR / Cas12b nuclease detection system; the method can realize constant temperature, rapid and accurate typing detection of SLCO1B1 gene on site, eliminate dependence on cold chain, preliminarily meet the requirements of grassroots community screening, provide technical support for accurate medication for patients with different genetic typing of hyperlipidemia, and is conducive to the promotion and application of on-site detection technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 : sgRNA sequence screening diagram in Example 1 of the present invention;

[0021] Figure 2 : sgRNA concentration screening diagram in Example 1 of the present invention;

[0022] Figure 3 : Feasibility diagram of CRISPR / Cas12b detecting SLCO1B1 gene polymorphism in Example 1 of the present invention;

[0023] Figure 4 : The protective effect of Cas12a vitrification protective agent on Cas12b reagent has been reported in Example 2 of the present invention;

[0024] Figure 5 : Screening of CRISPR / Cas12b detection reagent protective agent in Example 2 of the present invention;

[0025] Figure 6 : Screening diagram of the protective effect of maltodextrin at different concentrations in Example 2 of the present invention. DETAILED DESCRIPTION

[0026] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more definite definition of the protection scope of the present invention.

[0027] Example 1: sgRNA screening and kit feasibility verification

[0028] (1) Design and screening of sgRNA:

[0029] According to the SLCO1B1 gene mRNA coding sequence (Genbank Acc. No. NM_006446), five AapCas12b nuclease sgRNAs targeting the mutant bases were designed for the two SNP sites c.388 and c.521 (SEQ ID NO. 1-10). Shenzhen Shuxin Biotechnology Co., Ltd. was commissioned to synthesize sgRNA and single-stranded fluorescent probe (sequence 5'-FAM-TTATT-BHQ1-3').

[0030] Table 1: sgRNA sequences used

[0031]

[0032]

[0033]

[0034] Referring to the product manual of AapCas12b (Jiangsu Bristol-Myers Squibb Biotechnology Co., Ltd.), prepare 20 μL reaction solution, including: 600 nM Cas12b protein, 250 nM sgRNA, 10 × Cas12b reaction buffer, 20 U RNase inhibitor (Jiangsu Bristol-Myers Squibb Biotechnology Co., Ltd.) and 100 pg human SLCO1B1 coding sequence DNA fragment (synthesized by General Bio (Anhui) Co., Ltd.), 500 nM fluorescent probe. Place the reaction solution in a fluorescent quantitative PCR instrument, set the reaction temperature to 48 ° C for 30 minutes, and record the fluorescence signal intensity. Figure 1 As shown, c.388-sgRNA2 and c.521-sgRNA2 have the highest fluorescence signals, that is, the best detection efficiency.

[0035] Subsequently, the detection system was further optimized to screen the optimal concentration of sgRNA2. The concentrations of sgRNA2 in the reaction solution were adjusted to 100nM, 150nM, 200nM, 250nM, 300nM and 350nM, respectively. Figure 2 As shown, when the concentration of sgRNA2 is 250nM, the fluorescence value is significantly higher than other concentrations, and the detection efficiency is the highest. Therefore, the optimal concentration of sgRNA2 is determined to be 250nM.

[0036] (2) Feasibility of CRISPR / Cas12b detection method:

[0037] The SLCO1B1 gene c.388A>G site typing includes the following three types: wild-type homozygous 388AA, heterozygous 388AG, and mutant homozygous 388GG. The SLCO1B1 gene c.521T>C site typing includes the following three types: wild-type homozygous 521TT, heterozygous 521TC, and mutant homozygous 521CC. In order to verify the ability of this method to distinguish different genotypes, we tested DNA samples containing the above different genotypes respectively, and the reaction system was the same as above.

[0038] The results of the fluorescence quantitative PCR instrument showed that for both mutation sites, the fluorescence intensity of the mutant homozygote was the highest, while the fluorescence intensity of the wild-type homozygote was equivalent to that of the no-template control (NTC), and the fluorescence intensity of the heterozygote was between the former two ( Figure 3 A. Figure 3 B). When the reaction products are placed directly under a blue light instrument and observed with the naked eye, the mutant homozygote is the brightest, followed by the heterozygote, while the wild-type homozygote and the no-template control have basically no fluorescence ( Figure 3 C), indicating that CRISPR / Cas12b technology can effectively distinguish different genotypes of the two loci of SLCO1B1 by naked eye observation alone.

[0039] Example 2: Vitrification formula screening;

[0040] (1) Verify known Cas12 nuclease vitrification formulas;

[0041] Referring to the reported CRISPR / Cas12a nucleic acid detection system vitrification formula and process (Qian et al, Sensors and Actuators B: Chemical, 2020, 305: 127440), 0.02 g / mL trehalose and 0.1 g / mL pullulan (both purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.) were used as protective agents and mixed evenly with 20 μL CRISPR / Cas12b nucleic acid detection premix (containing 600 nM Cas12b protein, 250 nM sgRNA, 10×Cas12b reaction buffer, 20 U RNase inhibitor (RI), 500 nM fluorescent probe), and placed in a vacuum drying oven for drying at room temperature to prepare a vitrification reagent. The vacuum drying oven was evacuated with a pressure of 100 kPa and the drying time was 6 h to obtain a film-like vitrified product with good morphology.

[0042] In order to verify the room temperature storage stability of the vitrified preparation, an accelerated aging test was performed at 37°C. According to the Arrhenius equation in thermodynamics, if a reagent retains more than 80% of its activity after being stored at 37°C for 30 days, then it can be stored at 20-25°C for at least half a year.

[0043] After the vitrified preparation was stored at 37°C for 30 days, 20 μL of nuclease-free water was taken for reconstitution, 100 pg of human SLCO1B1 coding sequence DNA fragment was added, and the reaction was set at 48°C for 30 minutes. The fluorescence value was recorded and the remaining relative activity was calculated according to the following formula:

[0044]

[0045] The results showed that the relative activity of the vitrified preparation decreased to about 40% after being stored at 37°C for 30 days. Figure 4 ), indicating that the vitrification formula for Cas12a nuclease has a poor protective effect on Cas12b detection reagents, and it is necessary to select a new vitrification formula for Cas12b reagents with excellent protective effects.

[0046] (2) Screening of Cas12b premix vitrification additives;

[0047] Sodium carboxymethyl cellulose, pectin, trehalose and maltodextrin (all purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.) were selected as candidate protective agents to screen the effects of preparing Cas12b vitrification reagents using protective agents of different concentrations. The vitrification preparation conditions were a vacuum drying oven with a pumping pressure of 100 kPa and a drying time of 6 h.

[0048] After the prepared vitrified samples were aged at 37°C for 7 days, the two sites of SLCO1B1 were detected in the same manner as above. The non-vitrified premixed solution stored at -20°C was used as the positive control, the non-vitrified premixed solution stored at 37°C was used as the negative control, and deionized water was used as the blank control. The results are shown in Figure 5 As shown in the figure, the vitrified samples containing a certain concentration of sodium carboxymethyl cellulose or pectin basically lost their activity after 7 days at 37°C, and the detected fluorescence value was close to the negative control; after 7 days at 37°C, the detected fluorescence value of the trehalose vitrified preparation group was equivalent to more than 60% of the positive control; while maltodextrin showed a better protective effect, and the fluorescence values ​​of vitrified preparations prepared at different concentrations were all above 90% of the positive control after 7 days at 37°C. Therefore, maltodextrin was selected as the protective agent for the vitrification of CRISPR / Cas12b nucleic acid detection premix.

[0049] Furthermore, maltodextrin with a final concentration of 0.10 g / mL, 0.15 g / mL, 0.20 g / mL and 0.25 g / mL was mixed with the CRISPR / Cas12b detection premix, and a vitrified product was prepared according to the above conditions. The vitrified product was placed at 37°C for accelerated aging for 30 days, tested every 5 days, and the remaining relative activity was calculated. Figure 6It can be seen that the relative activity of the 0.10g / mL maltodextrin group dropped below 70% after 30 days at 37°C, and the enzyme activity loss was large, while the 0.20g / mL maltodextrin group still retained more than 80% relative activity after 30 days at 37°C, which was significantly higher than other concentrations (independent t test between two samples, p<0.05). Therefore, it can be determined that the vitrified preparation prepared at a final maltodextrin concentration of 0.20g / mL has the best protective effect.

[0050] (3) Optimization of vitrification drying process;

[0051] Based on the above results, the vitrification drying process was optimized to investigate the effects of the three factors of extraction pressure (A), drying temperature (B) and drying time (C) on the residual relative activity of the vitrification reagent at 37°C for 7 days. The pressure levels were set to 90, 95 and 100 Kpa, the drying temperatures were set to 15, 20 and 25°C, and the drying time levels were set to 4, 5 and 6 h, respectively. According to the Box-Behnken experimental design principle, the three-factor three-level response surface analysis experiment was performed using Design-Expert 11.0.6 software. The response surface factor level settings are shown in Table 2. The experimental results for detecting the c.388 site are shown in Table 3.

[0052] Table 2: Response surface factor analysis level coding

[0053]

[0054] Table 3: Response surface analysis experimental design and results

[0055]

[0056] The test results in Table 3 were subjected to regression analysis to obtain the quadratic polynomial regression equation of the residual enzyme activity of the vitrified preparation at 37°C for 7 days on the withdrawal pressure (A), drying temperature (B) and drying time (C): Y = 97.98 + 1.24A + 0.8388B + 0.47C + 0.6275AB + 0.30AC - 0.17BC - 2.32A 2 -1.29B 2 -0.6227C 2. The variance analysis of the regression equation shows that the order of factors affecting the residual enzyme activity of the vitrified preparation at 37°C for 7 days is: extraction pressure > drying temperature > drying time. The first-order partial derivative of the multivariate quadratic regression equation is obtained. When the response value relative to the residual activity reaches the maximum value, the optimal conditions of the three factors are extraction pressure of 96.728KPa, drying temperature of 21.908℃ and drying time of 5.408h, and the corresponding maximum value of the residual enzyme activity of the vitrified preparation at 37°C for 7 days is 98.448%. Considering the possibility of actual operation, the vitrification process of the CRISPR / Cas12b detection reagent was corrected to extraction pressure of 97KPa, drying temperature of 22℃ and drying time of 5.4h. The relative residual activity of the vitrified product obtained after process optimization is 98.18% at 37°C for 7 days, 95.43% at 15 days, and 88.36% at 30 days, which is significantly higher than the vitrification reagent without process optimization.

[0057] Example 3: Detection of clinical samples;

[0058] In order to verify the accuracy of this CRISPR / Cas12b detection method, the detection results of clinical blood DNA samples (provided by Lianyungang Traditional Chinese Medicine Hospital) prepared by the vitrification reagent prepared by this technology were compared with the commercially available human SLCO1B1 gene polymorphism detection kit (Shengxiang Biotechnology Co., Ltd.).

[0059] The commercially available SLCO1B1 gene polymorphism detection kit adopts the probe method fluorescence quantitative PCR technology. The reaction solution is prepared according to the kit instructions (wherein the amount of human genomic DNA added is 100 ng), and the fluorescence quantitative PCR reaction is performed and the results are analyzed according to the procedure recommended in the instructions.

[0060] The same human genomic DNA sample was detected using the CRISPR / Cas12b vitrification reagent prepared in Example 2, and the reaction conditions were the same as in Example 2, except that the amount of template genomic DNA was adjusted to 100 ng. After the reaction, a blue light instrument was used to irradiate, and the results were observed with the naked eye to judge the genotypes of different samples from the brightness. The results showed that the results of the two methods for detecting clinical DNA samples were highly consistent (Table 4, Table 5), proving that the CRISPR / Cas12b vitrification reagent of the present invention does not require DNA amplification, and can effectively genotype the c.388 and c.521 sites of the SLCO1B1 gene.

[0061] Table 4: Typing results of c.388 locus of clinical samples

[0062]

[0063]

[0064] Table 5: Typing results of c.521 locus of clinical samples

[0065]

[0066] The above embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.

Claims

1. A kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene, comprising two vitrified premixed reagents for detecting two SNP sites c.388A>G and c.521T>C, nuclease-free water and a colorimetric card, characterized in that: Both vitrification premix reagents are composed of 20 μL reaction premix and protective agent. In the vitrification premix reagent for detecting the c.388A>G site, the sgRNA sequence is shown as SEQ ID NO.2; in the vitrification premix reagent for detecting the c.521T>C site, the sgRNA sequence is shown as SEQ ID NO.

7.

2. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 1, characterized in that: The reaction premix contains 600nM Cas12b protein, 250nM sgRNA, 10×Cas12b reaction buffer, 20URNase inhibitor, and 500nM single-stranded DNA fluorescent probe.

3. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 2, characterized in that: The sequence of the single-stranded DNA fluorescent probe is 5'-FAM-TTATT-BHQ1-3'.

4. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 1, characterized in that: The protective agent in the vitrification premix reagent is maltodextrin, and the concentration is 0.10-0.30 g / mL.

5. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 4, characterized in that: The concentration of maltodextrin is 0.20 g / mL.

6. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 1, characterized in that: The preparation process of the vitrified premixed reagent is as follows: After the reaction premix is ​​fully mixed with the protective agent, it is placed in a vacuum drying oven for drying at a pumping pressure of 90 to 100 KPa, a drying temperature of 15 to 25° C., and a drying time of 4 to 6 hours.

7. The kit for rapid detection of single nucleotide polymorphism of human SLCO1B1 gene according to claim 6, characterized in that: The pumping pressure is 97KPa, the drying temperature is 22℃, and the drying time is 5.4h.

8. Use of the kit according to any one of claims 1 to 7 in detecting single nucleotide polymorphisms of SLCO1B1 gene, characterized in that: The specific detection steps are as follows: Step 1: Take 1 portion of each of the two vitrified premixed reagents and place them in PCR tubes. Add 20 μL of nuclease-free water to each tube to dissolve the vitrified premixed reagents. Step 2: Add 100 ng human genomic DNA sample to each tube; Step 3: react at 48°C for 30 min; Step 4: Illuminate with a blue light meter, observe the fluorescence brightness with the naked eye, and compare it with the colorimetric card; the brightest one is the mutant homozygote, the second brightest one is the heterozygote, and the one with no fluorescence is the wild-type homozygote.